Athenex's oral chemother­a­py for­mu­la­tion scores in piv­otal study; Gly­comine brings in $33M in Se­ries B haul

→ Athenex $AT­NX, whose plat­form tech­nol­o­gy is en­gi­neered to con­vert wide­ly-used in­tra­venous chemother­a­pies in­to oral drugs, said its oral for­mu­la­tion of pa­cli­tax­el met the main goal of con­fer­ring a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment over IV pa­cli­tax­el in a piv­otal study in­volv­ing metasta­t­ic breast can­cer pa­tients. The com­pa­ny is now in the process of putting to­geth­er a mar­ket­ing ap­pli­ca­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER